The Verdict
What the evidence shows, where it stops, and who should be cautious.
Opinion and access, not aggregation
A weekly longevity brief with a verdict, a price check, and a next step.
The Casanova Brief enters a crowded longevity media space by doing what research roundups cannot: giving patients a clear judgment, transparent cost context, regulatory caution, and a pathway into Casanova programs when appropriate.
Start free eligibility checkRecurring franchise
Four sections readers can recognize every week.
The Price Check
Cost ranges and access notes across US, Thailand, Vietnam, and Malaysia pathways.
Regulatory Watch
Jurisdiction, safety, licensing, and platform-claim risks before patients act.
Ask a Physician
Curated patient questions answered with physician review and sober boundaries.
Revenue model
Newsletter as funnel, sponsor placement, and member product.
Free tier
Ad-supported
Full weekly issue that grows the list and drives patient intake.
Paid tier
$15-25/mo
Early access, extended Price Check data, Ask-a-Physician submission, and monthly deep dive.
Sponsors
Rate card
One visually distinct sponsor slot per issue, pulled from the existing Sponsors program.
Referral tie-in
Tracked
Verdict and Price Check sections connect to Casanova programs and ambassador codes where compliant.
Compliance guardrails
Editorial first. Sponsors never write the verdict.
No outcome claims in subject lines or preview text. Sponsor placements stay visually distinct from editorial content. Named institutions appear only where licensing and therapy availability have been confirmed.
Cross-sell loop
Want a second opinion on any of this?
Every Brief issue should lead interested readers into a free eligibility check, while program pages should invite patients back into the Brief for the research behind Reset, Restore, and Renew.
Start free eligibility check